Literature DB >> 19327866

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer.

Emilio Bria1, Michele Milella, Isabella Sperduti, Gabriele Alessandrini, Paolo Visca, Felicita Corzani, Diana Giannarelli, Virna Cerasoli, Federica Cuppone, Fabiana Letizia Cecere, Antonio Marchetti, Rocco Sacco, Felice Mucilli, Sara Malatesta, Luigi Guetti, Luca Vitale, Anna Ceribelli, Massimo Rinaldi, Edmondo Terzoli, Francesco Cognetti, Francesco Facciolo.   

Abstract

BACKGROUND: The number of resected lymph-nodes (#RNs) has proven prognostic in breast and colorectal cancer. Here we evaluated its prognostic impact in a series of resected NSCLC patients.
METHODS: A panel of established prognostic factors plus (1) #RNs or (2) the ratio between the number of metastatic nodes and #RNs (NR) were correlated to overall- (OS), cancer-specific- (CSS), and disease-free-survival (DFS), using the Cox-model. Risk-classes according to hazard ratios (HR) were generated. Internal and external validation was accomplished.
RESULTS: A dataset of 415 resected NSCLC patients was retrieved. At multivariate analysis, #RNs and NR were independent factor for longer OS, CSS and DFS (p<0.0001). Patients with a #RNs>10 (identified optimal cut-off) had a statistically significant OS (p=0.02) and DFS (p=0.0005) benefit. In node-positive patients, a NR<9% significantly correlated with better outcome. Stratification into High-, Medium-, and Low-Risk classes, based on High- (HRFs: stage, N-status, age, #RNs) and Intermediate-Risk Factors (IRFs: sex, grading, histology), efficiently predicted outcomes (p<0.0001). The risk class model performance was externally validated in and independent dataset of 297 patients.
CONCLUSIONS: These results contribute to complete the panel of prognostic factors for resected NSCLC. A prospective larger validation and comparison with molecular prognostic tools is warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19327866     DOI: 10.1016/j.lungcan.2009.02.024

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  33 in total

1.  Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.

Authors:  Chang-Li Wang; Yue Li; Dong-Sheng Yue; Lian-Min Zhang; Zhen-Fa Zhang; Bing-Sheng Sun
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model.

Authors:  Ulas Kumbasar; Hilgardt Raubenheimer; May Al Sahaf; Nizar Asadi; Maria Elena Cufari; Chiara Proli; Periklis Perikleous; Zakiyah Niwaz; Emma Beddow; Vladimir Anikin; Niall McGonigle; Simon Jordan; George Ladas; Michael Dusmet; Eric Lim
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Can mathematics replace anatomy to establish recommendations in lung cancer surgery?

Authors:  Marc Riquet; Ciprian Pricopi; Antoine Legras; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

4.  Impact of lymph node management on resectable non-small cell lung cancer patients.

Authors:  Apichat Tantraworasin; Somcharoen Saeteng; Sophon Siwachat; Tawatchai Jiarawasupornchai; Nirush Lertprasertsuke; Sarawut Kongkarnka; Chidchanok Ruengorn; Jayanton Patumanond; Emanuela Taioli; Raja M Flores
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer.

Authors:  Chukwumere E Nwogu; Adrienne Groman; Daniel Fahey; Sai Yendamuri; Elisabeth Dexter; Todd L Demmy; Austin Miller; Mary Reid
Journal:  Ann Thorac Surg       Date:  2012-03-20       Impact factor: 4.330

6.  Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis.

Authors:  Giovanni Leuzzi; Filippo Lococo; Gabriele Alessandrini; Isabella Sperduti; Lorenzo Spaggiari; Federico Venuta; Erino A Rendina; Pierluigi M Granone; Cristian Rapicetta; Piero Zannini; Gaetano Di Rienzo; Maurizio Nicolosi; Francesco Facciolo
Journal:  Lung       Date:  2016-10-13       Impact factor: 2.584

7.  Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Qian Li; Ping Zhan; Dongmei Yuan; Tangfeng Lv; Alexander Sasha Krupnick; Antonio Passaro; Alessandro Brunelli; Matthew P Smeltzer; Raymond U Osarogiagbon; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

8.  Relationship of immunohistochemical biomarker expression and lymph node involvement in patients undergoing surgical treatment of NSCLC with long-term follow-up.

Authors:  Ana María Gómez; Jose Ramón Jarabo Sarceda; Jose Antonio L García-Asenjo; Cristina Fernandez; Susana Hernandez; Julian Sanz; Elena Fernandez; Joaquin Calatayud; Antonio Torres; Florentino Hernando
Journal:  Tumour Biol       Date:  2014-01-19

9.  Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base.

Authors:  Onkar V Khullar; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez
Journal:  J Am Coll Surg       Date:  2014-10-27       Impact factor: 6.113

10.  Does the extent of lymph nodes dissection affect the prognosis of resected stage IA non-small cell lung cancer?

Authors:  F Xu; C Wang; L Qi; W Yu; Q Li
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.